Related Experiment Video
Updated: Jul 5, 2026
03:32
Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
[Concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma]
Yoichi Ikeda1, Mamoru Tsukuda, Yuji Tanigaki
1Dept. of Otolaryngology, Fujisawa City Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 20, 2008
Summary
Concurrent chemoradiotherapy with S-1 chemotherapy is effective for T2N0 glottic carcinoma, achieving larynx preservation and no recurrences in a pilot study. Further long-term follow-up is needed.
Area of Science:
- Oncology
- Head and Neck Surgery
- Radiation Oncology
Context:
- Early glottic carcinoma treatment aims for larynx preservation.
- Radiotherapy alone is effective for T1N0, but T2N0 larynx preservation rates (72-85%) require improvement.
- Treatment strategies for T2N0 glottic carcinoma vary, necessitating optimized approaches.
Purpose:
- To evaluate the efficacy of concurrent chemoradiotherapy using S-1 for T2N0 glottic carcinoma.
- To assess larynx preservation rates and treatment outcomes in patients with T2N0 glottic squamous cell carcinoma.
Summary:
- A study involving 12 patients with T2N0 glottic squamous cell carcinoma investigated concurrent chemoradiotherapy with S-1 (80-100 mg/day) and irradiation (60-70 Gy).
- Patients received a 2-week S-1 cycle with a 1-week rest during irradiation.
- All patients achieved pathological complete response (pCR) with no recurrences observed at the primary sites during the follow-up period.
Impact:
- Concurrent chemoradiotherapy with S-1 demonstrated efficacy for T2N0 glottic carcinoma, achieving high larynx preservation rates.
- The treatment showed manageable adverse events, with no treatment cancellations or interruptions.
- Results support further investigation with long-term follow-up to confirm the efficacy and safety of this treatment modality.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...